“…Commercial CMMSs use silicon-chip or glass-chip technologies (such as the Bionas Discovery ® 2500 analyzing system (Bionas GmbH, Rostock, Germany) and the MEA2100-System (Multi Channel Systems, Reutlingen, Germany)) [ 1 , 2 , 20 ]. The current focus of the field is improving the cell-culture properties of such systems and their capacities for biochemical analysis and clinical diagnostic applications, such as conducting polymerase-chain reactions and patch clamping [ 3 , 21 , 22 ]. Commercial glass-based systems in the 96 well-plate format, such as the Bionas Discovery ® adcon Reader (Bionas GmbH, Rostock, Germany) and the Roche xCELLigence System (Roche Life Science, Barcelona, Spain), allow detecting changes in cell adhesion over seconds or days.…”